Patents by Inventor Tatyana Chernova
Tatyana Chernova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7709214Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 20, 2007Date of Patent: May 4, 2010Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLCInventors: Gordon J. Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
-
Patent number: 7635757Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: January 26, 2006Date of Patent: December 22, 2009Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Patent number: 7432059Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. The invention further provides methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1-mediated signal. Diagnostic and treatment methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 28, 2001Date of Patent: October 7, 2008Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC, Brigham and Women's HospitalInventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood, Yvette Latchman, Arlene H. Sharpe
-
Publication number: 20080118511Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 20, 2007Publication date: May 22, 2008Applicants: Dana-Farber Cancer Institute, Inc., Genetics Institute LLCInventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
-
Publication number: 20060153841Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 26, 2006Publication date: July 13, 2006Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Patent number: 7038013Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 2, 2001Date of Patent: May 2, 2006Assignee: Dana-Faber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Patent number: 6936704Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 23, 2000Date of Patent: August 30, 2005Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich
-
Publication number: 20020164600Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 28, 2001Publication date: November 7, 2002Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood
-
Publication number: 20020110836Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 28, 2001Publication date: August 15, 2002Inventors: Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive Wood, Yvette Latchman, Arlene H. Sharpe
-
Publication number: 20020102651Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: November 2, 2001Publication date: August 1, 2002Applicant: Dana Farber Cancer Institute, Inc.Inventors: Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich